Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

Mon, 01st Jun 2020 11:16

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Monday and not separately reported by Alliance News:

----------

Fuller Smith & Turner PLC - pubs - To issue commercial paper under Covid Corporate Financing facility for initial sum of GBP100 million, allowing GBP155 million revolving credit facility to remain undrawn. Placed 96% of employees on furlough, while executives and board members volunteered for pay reduction.

----------

Arricano Real Estate PLC - property - All five shopping centres in Ukraine open with effect on Saturday last week, as restrictions by local authorities on access to shopping centres lifted. However, food courts, cinema and entertainment centres will remain closed.

----------

Topps Tiles PLC - tile retail - To sale and leaseback head office in Enderby, Leicester, to UK Warehouse Properties Ltd for GBP18.1 million. Proceeds expected to strengthen group's financial position in the face of the Covid-19 crisis.

----------

Mattioli Woods PLC - wealth management - Annual revenue to be ahead of GBP58.5 million reported the year before. Profit to be ahead of management expectations. Directors to take 50% reduction in salaries and fees until end of June, while chief executive officer takes no salary at all. Group in strong financial position following the acquisition of Hurley Partners in March.

----------

Motif Bio PLC - cash shell - Remains in negotiations with several reverse takeover candidates in the healthcare sector, as the pandemic creates new opportunities for healthcare firms.

----------

CloudCall Group PLC - communications - Expects to have enough cash to fund it through period of macroeconomic uncertainty. Continues to report ongoing challenges within the broader marketplace, which has near-term impact on the sales pipeline. Year-to-date sales bookings from new customers 28% less than same period the year before.

----------

Zoetic International PLC - cannabidiol - Signs distribution agreement with partner BettermentRS to market tobacco-alternative Chill products to its network of outlets. Rollout of Chill brand delayed by pandemic, as many retail outlets closed on lockdown restrictions.

----------

MJ Hudson Group PLC - asset management - Reports strong sales activity and levels of client work during lockdown period. Confident in achieving profit for year ending June 30 in line with market expectations, despite revenue disruption due to the lack of new fund launch activity.

----------

Marshall Motor Holdings PLC - cars - Trading significantly ahead of UK market in first quarter of 2020. As lockdown eases, group gradually expanded its offering of aftersales services, with initial demand encouraging. Furloughed 90% of employees during lockdown period as many stores closed. To post a pretax loss for the first half of 2020.

----------

Braveheart Investment Group PLC - investments - Subsidiary Paraytec Ltd to launch project with University of Sheffield to develop a rapid test for Covid-19 test, which will utilise highly sensitive light-based detection system coupled with a molecular "affinity" device to capture Covid-19 virus particles. Paraytec to own all foreground intellectual property generated by the project.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Jul 2015 06:40

Motif Bio's Iclaprim Eligible For Incentives With New US Designation

Read more
23 Jun 2015 11:20

Motif Bio raises £22m via share placing

Biopharmaceutical company Motif Bio has raised £22m via a conditional share placing with institutional investors. The London-listed group said "the placing is conditional on securing shareholder approval and on a successful qualified infection disease product designation being given to its iclaprim

Read more
23 Jun 2015 09:28

Amphion Innovations Confident After Motif IPO, 2014 Asset Value Fall

Read more
23 Jun 2015 06:58

Motif Bio Raises GBP22 Million In Discounted Share Placing (ALLISS)

Read more
9 Jun 2015 08:27

Motif Bio Annual Loss Widened Slightly Ahead Of London IPO

Read more
1 Jun 2015 11:15

Motif Bio signs deal with leading clinical research organisation

A wholly-owned subsidiary of antibiotic developer Motif Bio has signed letters of intent and interim agreements with a leading global clinical research organisation (CRO). Motif has agreed to invest more than $0.95m under the agreements, which must be paid by the end of July. Under the agreements,

Read more
1 Jun 2015 07:23

Motif Bio Shares Up As It Moves Towards Iclaprim Clinical Trials

Read more
28 May 2015 09:47

Motif Bio Gets FDA Minutes Confirming Phase III Plans For Iclaprim

Read more
7 May 2015 09:12

Motif Bio Exploring Funding Options For Iclaprim Trials (ALLISS)

Read more
15 Apr 2015 07:31

LONDON MORNING BRIEFING: Next And Burberry Shares In Fashion

Read more
15 Apr 2015 07:10

Amphion Shares Up As Motif Bio Gets US FDA Approval For Iclaprim Trial

Read more
2 Apr 2015 11:46

Motif Bio makes AIM debut, seeks approval for Iclaprim treatment

Clinical stage biopharmaceutical group Motif Bio began trading on AIM on Thursday, after raising £2.8m in its initial public offering. The group, whose 44.09% of issued equity is owned by Amphion, placed shares at 20p each, said it had 64,238,442 ordinary shares in issue and a market capitalisation

Read more
2 Apr 2015 08:19

BCA Marketplace, Marshall Motor And Motif Bio Begin Trading (ALLIPO)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.